Close Menu

NEW YORK (360Dx) – TearLab today announced it has submitted a 510(k) application to the US Food and Drug Administration for its TearLab Discovery Platform, an in vitro diagnostic testing system for ophthalmic conditions.

The submission also covers a test card measuring the inflammatory biomarker MMP-9, TearLab said, adding the TearLab Discovery platform will be able to perform its current FDA-cleared tear osmolarity test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.